Navigation Links
Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™
Date:2/15/2011

uorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information please visit www.pfenex.com

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending 21% of net sales in its largest business segment Prescription Medicines on research and development.

For more information please visit www.boehringer-ingelheim.com.

Today, Boehringer Ingelheim is one of the world's leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer Ingelheim delivers services for pre-clinical development up to global market supply with a strong commitment to its customers at its manufacturing facilities for mammalian cell culture and microbial fermentation. Boehringer Ingelheim has brought 18 molecules to market and has  many  years  of  experience  in  multiple  molecule  classes  such  as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules and plasmid DNA. Furthermore, high-titer platform technologies for new antibody mimetic formats such as scaffold proteins and antibody fragments are available for the manufacture of customer products
'/>"/>

SOURCE Pfenex Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
2. Pfenex Inc. Awarded Contract With the United States Federal Government Potentially Totaling Up to $18.8 Million to Develop a Robust Pfenex Expression Technology Based Process for the Production of Bulk Recombinant Protective Antigen (rPA) From Anthr
3. Pfenex Inc. Establishes Reagent Protein Distribution Agreement With Cedarlane Corporation
4. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
5. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
6. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
7. Boehringer Ingelheim Unveils Diabetes Pipeline
8. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
9. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
10. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
11. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
(Date:1/14/2014)... HILLSBORO, Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- ... and a targeting guide with accompanying instrumentation to place ... new adjunct to the soft tissue (e.g. ligament) repair ... soft tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Conn., Sept. 21 In a platform presentation at ... the Study of Diabetes (EASD) in Stockholm, investigators for ... the results of a clinical study evaluating a new ... (Profil Institute for Metabolic Research, Neuss, Germany) and colleagues ...
... Inc. (Nasdaq: VVUS ) today announced positive ... Controlled Release Capsules, an investigational therapy for treatment of ... Americans. The findings come from the ... subset of patients who completed the previously reported 56-week ...
Cached Medicine Technology:Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting 2Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting 3New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 2New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 3New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 4New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 5New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 6
(Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
(Date:4/23/2014)... TORONTO, April 24, 2014 Pregnant immigrants from ... require increased monitoring during pregnancy, according to new ... published today in the British Journal of ... preeclampsia and eclampsia rates among immigrants and native-born ... Canada (Ontario), Denmark, Sweden, Spain (Catalonia and Valencia) ...
(Date:4/23/2014)... American Society for Radiation Oncology (ASTRO) has issued ... Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline," ... in the treatment of endometrial cancer. The guideline,s ... issue of Practical Radiation Oncology (PRO), ... full-length guideline is available as an open-access article ...
(Date:4/23/2014)... of the gastro-intestinal tract has long been considered to ... the Sahlgrenska Academy have used refined microscopic techniques that ... surface of the gastro-intestinal tract is only as large ... , The digestive tract, which passes from the mouth ... a length of about 5 meters in a normal ...
(Date:4/23/2014)... the potential health benefits of probiotics, antioxidants and other ... And the chemical industry is getting in on the ... deter growth, so the industry is responding with clinical ... cover story in Chemical & Engineering News ... Society. , Melody M. Bomgardner, a senior editor at ...
Breaking Medicine News(10 mins):Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2
... , WASHINGTON , Jan. 29 In today,s ... Bipartisan Policy Center,s (BPC) plan for reforming health care, entitled: ... as a bipartisan health care proposal that is worthy of ... plan, which was developed by former U.S. Senate Majority Leaders ...
... more likely to strike whites than blacks, researchers find , ... its kind finds that Parkinson,s disease in the United States ... whites and Hispanics are twice as likely to develop the ... an analysis of data from 36 million Medicare recipients, are ...
... The Minnesota Medical Association Board of Trustees decided Saturday ... Assistance Medical Care (GAMC) program, but not if such efforts include ... not cover the cost of providing care. , The Board also ... programs. The MMA sent a letter to lawmakers this week. , ...
... New collaboration leverages Joslin,s deep clinical and research expertise and ... BOSTON , Jan. 29 Joslin.org ... Center, the world,s preeminent diabetes research and clinical care organization, and ... with diabetes, today announced a new online partnership. dLife will ...
... quite some time, the "Holy Grail" in medical imaging has ... death as a means to intervene early in diseases and ... researchers at the University of Notre Dame and the Washington ... synthetic probe to target dead and dying cells in mammary ...
... Both ... symptoms of autism with a Biomedical alternative. , ... (PRWEB) January 29, 2010 -- Autism-supplements.com, a Lyndhurst New ... Jenny McCarthy and Jim Carrey’s autism organization, to help raise money and public awareness ...
Cached Medicine News:Health News:President Obama Highlights Bipartisan Policy Center Health Care Reform Plan in Remarks to House Republicans 2Health News:President Obama Highlights Bipartisan Policy Center Health Care Reform Plan in Remarks to House Republicans 3Health News:Parkinson's More Common in Northeast, Midwest 2Health News:Doctors Tell Lawmakers to Find a New GAMC Fix 2Health News:Joslin Diabetes Center and dLife Form New Online Partnership 2Health News:Joslin Diabetes Center and dLife Form New Online Partnership 3Health News:New paper describes important advance in imaging of cell death 2Health News:Autism-Supplements.com and Generation Rescue Work Together to Raise Money for Biomedical Autism Treatments 2
The Model 305 is a hand-held, portable, lightweight oximeter designed for spot checking. It has a NiCad rechargeable battery....
A pocket-sized pulse oximeter. Perfect for the physician's office, emergency medicine, hospitals and clinics, and home health care....
... Cost-effective, portable, continuous, or spot ... with alarms and an internal ... and Sleep Study modes make ... the hospital or clinical environment; ...
... Sleep Hand-Held Pulse Oximeter with built-in ... sleep screening studies in the sleep ... With its easy-to-use, 2-key operation, it ... of SpO 2 , pulse rate ...
Medicine Products: